In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Merck & Company (MRK – Research Report), with a price ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...

The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

Of the three stocks in the index that were trading lower in Friday morning, all of them feature an ampersand: JPMorgan Chase & Co, Johnson & Johnson, and Merck & Co. The only other Dow stock that ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y.

Merck (NYSE:MRK) is preparing to launch a subcutaneously ... in 2025," said MRK CEO Robert Davis on Monday at the JPMorgan Healthcare Conference in San Francisco. "That's actually new information ...